Diabetic retinopathy
Therapeutic area
Metabolic Disease
Rare disease
No
- Definition
- A chronic, pathological complication associated with diabetes mellitus, where retinal damages are incurred due to microaneurysms in the vasculature of the retina, progressively leading to abnormal blood vessel growth, and swelling and leaking of fluid from blood vessels, resulting in vision loss or blindness.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Diabetic retinopathy
- Therapeutic area
- Metabolic Disease
- diabetic retinopathy
- DRD
- diabetic retinal disease
- Severity
- Severe
- Cardiology
- Metabolic Disease
- Neurology
- Ophthalmology
- Vascular Medicine
- MONDO ID
- MONDO:0005266
- Parent condition
- MONDO:0002311
Related records
Broader conditions (15)
- Cardiovascular disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disorder of orbital region
- Disorder of visual system
- Eye disorder
- Human disease
- Metabolic disease
- Nervous system disorder
- Neurovascular disorder
- Ocular vascular disorder
- Retinal disorder
- Retinal vascular disorder
- Vascular disorder
Narrower conditions (4)
- Background diabetic retinopathy
- Diabetic macular edema
- Proliferative diabetic retinopathy
- Severe nonproliferative diabetic retinopathy
Trials (671)
- "My Eyes, My Light": Amar Chokh, Amar Alo
- 10-year Progression of Diabetic Retinopathy: Identification of Signs and Surrogate Outcomes
- 20- Versus 23- Gauge System for Pars Plana Vitrectomy
- 3 Month Outcome of Ziv-aflibercept for DME
- 4D-150 in Patients With Diabetic Macular Edema
- A Blinded, Self-control Trial to Evaluate an Artificial Intelligence Based CAD System for Diabetic Retinography
- A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
- A Comparison of Islet Cell Transplantation With Medical Therapy for the Treatment of Diabetic Eye Disease
- A Comparison of Standard Laser With Micropulse Laser for the Treatment of Diabetic Macular Oedema.
- A Comparison of the Checkup Vision Assessment System to Standard Vision Assessment Tools
- A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
- A Longitudinal Study of Choroidal Changes After Cataract Surgery in Eyes With Diabetic Retinopathy
- A Multi-center Study on the Artificial Intelligence Enabled Diabetic Retinopathy Screening Based on Fundus Images
- A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy
- A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
- A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
- A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon®
- A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
Approved drugs (4)
- Aflibercept
- Captopril
- Dexamethasone
- Ranibizumab
Drugs in development (38)
- Anecortave acetate Phase 1
- APX-3330 Phase 2
- Aspirin Phase 3
- Bevacizumab Phase 3
- Brimonidine Phase 2
- Carbidopa Early phase 1
- Dapagliflozin Phase 3
- Darapladib Phase 2
- Doxycycline Phase 2
- Fenofibrate Phase 3
- Gersizangitide Phase 1
- Insulin glargine Early phase 1
- Ketorolac Phase 1
- Lazucirnon Phase 2
- Levodopa Early phase 1
- Metformin Early phase 1
- Migaldendranib Phase 1
- Nesvategrast isobutanolammonium Phase 2
- Octreotide acetate Phase 3
- OSI-632 Phase 1
Other linked drugs (3)
- Calcium dobesilate
- Finerenone
- Hydralazine hydrochloride